Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
